A US Retrospective Claims Analysis Comparing Healthcare Costs of Patients Transitioning from Immediate-Release Oxycodone to Two Different Formulations of Extended-Release Oxycodone: Xtampza ER or OxyContin.
| Autor: | Olatoke O; HEOR Department, ZRx Outcomes Research, Mississauga, Ontario, Canada., Zah V; HEOR Department, ZRx Outcomes Research, Mississauga, Ontario, Canada., Stanicic F; HEOR Department, ZRx Outcomes Research, Mississauga, Ontario, Canada., Vukicevic D; HEOR Department, ZRx Outcomes Research, Mississauga, Ontario, Canada., Yfantopoulos P; HEOR Department, ZRx Outcomes Research, Mississauga, Ontario, Canada., Thompson C; Medical Department, Collegium Pharmaceutical Inc., Stoughton, MA, USA., DeGeorge MK; Medical Department, Collegium Pharmaceutical Inc., Stoughton, MA, USA., Passik S; Medical Department, Collegium Pharmaceutical Inc., Stoughton, MA, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | ClinicoEconomics and outcomes research : CEOR [Clinicoecon Outcomes Res] 2022 Mar 03; Vol. 14, pp. 119-128. Date of Electronic Publication: 2022 Mar 03 (Print Publication: 2022). |
| DOI: | 10.2147/CEOR.S340290 |
| Abstrakt: | Purpose: Opioid therapy for managing chronic pain remains a challenge, as providers must weigh the medical benefit to the patient with the risk of adverse events. Manipulation of many extended-release (ER) opioid formulations may lead to increased serious medical outcomes or death. The economic burden of opioid use disorders due to opioid misuse and abuse may vary depending on which abuse deterrent opioid formulation is prescribed. The study aimed to compare demographic and clinical characteristics and healthcare costs of chronic pain patients treated with two different abuse-deterrent opioid formulations, Xtampza ER and reformulated OxyContin. Methods: The source of data was IBM ® MarketScan ® Commercial Claims and Encounters Medicare Supplemental database, from January 2016 through February 2020. Patients with chronic pain were assigned to either the Xtampza ER or the OxyContin cohort based on the initial ER opioid prescription set as the index date. Continuous healthcare coverage was required during a minimum 3-month pre-index and 9-month post-index periods. Pre-index patients' characteristics were analyzed. Healthcare costs of Xtampza ER vs OxyContin were assessed in the post-index period. Results: After applying selection criteria, 464 patients were observed in the Xtampza ER cohort versus 1927 patients in the OxyContin cohort. In unmatched patients, ER opioid costs were lower for Xtampza ER than OxyContin ($2645 vs $3141; p <0.001), which ultimately led to lower total prescription costs for the Xtampza ER cohort compared to the OxyContin cohort ($7492 vs $8754; p =0.016). In matched patients, the total healthcare costs were significantly lower in the Xtampza ER cohort than in the OxyContin cohort, $22,630 vs $28,386 ( p =0.005), respectively. Conclusion: This study suggests that Xtampza ER may result in lower healthcare costs than OxyContin for a population of chronic pain patients switching from immediate release oxycodone based on real-world data. Competing Interests: OO, VZ, FS, DV, and PY are employees of ZRx Outcomes Research. VZ reports grants and/or personal fees from Glympse Bio, HutchMed Pharmaceuticals, Endo Pharmaceuticals, Stealth Biotherapeutics, RedHill Pharmaceuticals, and Collegium Pharmaceuticals, outside the submitted work. FS reports grants from Collegium Pharmaceutical Inc., during the conduct of the study. DV reports grants from Collegium Pharmaceutical, Inc., during the conduct of the study. CT, MKDG, and SP are employees of Collegium Pharmaceutical, Inc. The authors’ competing interests had no influence on study design, interpretation of the results or impose a censoring of the obtained results. The authors declare no other competing interest. (© 2022 Olatoke et al.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|